Different from breast cancers, expressing HER2D16 generates osimertinib resistance to EGFR T790M/L858R-mutant NSCLC cells in a Src-independent fashion through Src-bypass signaling, which was insensitive to Src inhibition with or without osimertinib (40, 41). Here, SRC is linked to non-small cell lung carcinoma.